Retatrutide appears to be a new treatment in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in research studies. By activating these receptors, Retatrutide suppresses appetite, {promotesinsulin secretion, and ultimately leads to significant reduction in body mass